BICC1 and fatty liver disease: The lack of known targets both in general cell lines and in liver tissue for potential RNA targets of Bicc1, such as miRNAs and LncRNAs (Tran et al., 2010), further highlights deficiencies that need to be addressed before a proper assessment can be made of how many of the unaccounted expression changes are due to such secondary effects, but the finding of Bicc1 to be altered in hepatic steatosis-driven fibrosis (Ramnath et al., 2018) further underscores the relevance of such interactions and the importance of focusing associated investigations specifically in the liver system.